Videos and Recordings

Videos and Recordings

January 17, 2020
In this conversation with Anne Mostue, Quanterix Chairman and CEO, Kevin Hrusovsky highlights 2019 successes and plans for the future.
January 16, 2020
Quanterix CEO Kevin Hrusovsky presents at the 38th Annual J.P Morgan Healthcare Conference. Access the Webcast and Q&A
October 08, 2019
Our CEO Kevin Hrusovsky joined Lyanne Alfaro on set of Nasdaq's
June 28, 2019
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Kevin Hrusovsky, Chairman and CEO of Quanterix, and Founder of Powering Precision Health (PPH), has been
June 24, 2019
Delivering ultrasensitive biomarker measurement you can count on.
June 24, 2019
Ultra-Sensitive Biomarker Measurement in Neurology Research using Simoa Technology. Utilization of Blood Biomarkers in Neurodegenerative Disease Research Biomarker World Congress and IO Pharma Congress, World Pharma Week, June 2019
June 24, 2019
The ultra-sensitive measurement of proteins as biomarkers of Immuno-Oncology therapeutics using Simoa platforms.  Biomarker World Congress and IO Pharma Congress, World Pharma Week, June 2019
June 10, 2019
CEO Kevin Hrusovsky took the stage in front of an enthusiastic audience this week at the BIO International Convention to share how Quanterix Simoa® ultra-sensitive biomarker technology platforms are disrupting healthcare and propelling drug discovery forward.
Bloomberg Radio Interview | February 07, 2019
In a conversation with Tom Moroney and Peter Barnes that highlights the power of the protein, Quanterix CEO Kevin Hrusovsky explains how Simoa is powering advances in research, specifically for the detection and treatment of Alzheimer’s and other neurodegenerative diseases.  
WCVB News Boston | February 06, 2019
WCVB's Emily Reimer explores Quanterix' next generation Simoa planar array technology.